Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
DANHEP is a cluster randomized study of two different low molecular weight heparins. Parenteral anticoagulants are used in a variety of settings, including treatment and prevention of venous thromboembolism in cancer patients, medical patients, and surgical patients, along with the use as adjuvant therapy for coronary syndromes. The most frequently used parenteral anticoagulants in Denmark, include the two different low molecular weight heparins; dalteparin and tinzaparin. The two drugs are considered equally efficient and safe regarding treatment and prevention of thrombosis and risk of bleeding. Importantly, there is a lack of evidence regarding whether these drugs are in fact comparable. The aim of this study is therefore to investigate the comparative safety and efficacy of the two different low molecular weight heparins (dalteparin and tinzaparin using cluster randomization in patients with an indication for low molecular weight heparins.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dalteparin | Active Comparator |
| |
| Tinzaparin | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dalteparin Prefilled Syringe | Drug | Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour. |
| Measure | Description | Time Frame |
|---|---|---|
| 30-day all-cause mortality and bleeding requiring blood transfusion | To evaluate whether treatment with any of the low molecular weight heparins will increase the risk of bleeding requiring blood transfusion during admission or death within 30 days in patients with indication for low molecular weight heparins. | 30 days |
| Measure | Description | Time Frame |
|---|---|---|
| 30-day all-cause mortality | Risk of all-cause mortality within 30 days of administering one of the studied drugs | 30 days |
| 365-day all-cause mortality | Risk of all-cause mortality within 365 days of administering one of the studied drugs |
| Measure | Description | Time Frame |
|---|---|---|
| Pregnancy loss | Risk of pregnancy loss during treatment with either of the two drugs studied | 9 months |
| Stillbirth | Risk of stillbirth during treatment with either of the two drugs studied |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Kasper Iversen, Professor, MD | Contact | + 45 28712753 | Kasper.Karmark.Iversen@regionh.dk | |
| Lars Køber, Professor, MD | Contact | + 45 35458525 | lars.koeber01@regionh.dk |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Amager-Hvidovre Hospital | Recruiting | Copenhagen | Denmark |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D054556 | Venous Thromboembolism |
| ID | Term |
|---|---|
| D013923 | Thromboembolism |
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Tinzaparin profiled syringe | Drug | Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour. |
|
| 365 days |
| Blood transfusion during admission | Blood transfusion defined from use of blood products | 90 days |
| 90 day risk of pulmonary embolism | Risk of pulmonary embolism within 90 days of administering one of the drugs studied | 90 days |
| 90 day risk of deep venous thrombosis | Risk of pulmonary embolism within 90 days of administering one of the drugs studied | 90 days |
| Heparin induced thrombocytopenia | Risk of heparin induced thrombocytopenia defined by; thrombocytes less than 150 x 109/l and presence of HIT antibodies | 90 days |
| Liver failure | Risk of liver failure defined by ALAT 3X upper limit of normal | 90 days |
| Length of hospital admission | Length of hospital admission | Admission time (up to 1 year from inclusion measured in days) |
| Days alive out of hospital | Days alive out of hospital | Time out of hospital (up to 1 year from inclusion measured in days) |
| 9 months |
| Antepartum bleeding | Risk of antepartum bleeding during treatment with either of the two drugs studied | 9 months |
| Postpartum bleeding | Risk of postpartum bleeding during treatment with either of the two drugs studied | up to 365 days |
| Placental complications | Risk of placental complications (Abruptio placenta, placenta prevue) during treatment with either of the two drugs studied | 9 months |
| Preeclampsia | Risk of preeclampsia and eclampsia during treatment with either of the two drugs studied | 9 months |
| Frederiksberg and Bispebjerg Hospital | Recruiting | Copenhagen | Denmark |
|
| Rigshospitalet | Recruiting | Copenhagen | Denmark |
|
| Herlev and Gentofte Hospital | Recruiting | Herlev | 2730 | Denmark |
|
| Nordsjællands Hospital | Recruiting | Hillerød | Denmark |
|
| Nykøbing Falster Hospital | Recruiting | Nykøbing Falster | Denmark |
|
| Næstved, Ringsted, Slagelse Hospital | Recruiting | Næstved | Denmark |
|
| Roskilde, Køge Hospital | Recruiting | Roskilde | Denmark |
|
| Bornholm Hospital | Recruiting | Rønne | Denmark |
|